Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine

AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice - eBioMedicine

RCSB PDB - 8BYU: Crystal Structure of HexaBody-CD38 Fab in complex with CD38

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. - Abstract - Europe PMC

PDF) Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors

IFN-γ independent markers of Mycobacterium tuberculosis exposure among male South African gold miners - eBioMedicine

Monoclonal Antibodies in Cancer

Multi-targeted immunotherapeutics to treat B cell malignancies - ScienceDirect

PDF) Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma

Multi-targeted immunotherapeutics to treat B cell malignancies - ScienceDirect

Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells

AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice - eBioMedicine

IJMS, Free Full-Text

Ida H Hiemstra's research works Genmab, Copenhagen and other places

PDF) Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma

CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells. - Abstract - Europe PMC